Are you not paying attention?
I am equally frustrated that IMU shareholders have not received clinical trial updates from the open label Vaxinia MAST trial. If any of you have ever doubted the credibility of Paul Hopper or Prof. Yuman Fong, you really should take notice of the following and ask yourself: was the licensing of CF33 for investors or for PH and YF. I encourage you to specifically look towards the end of this post and determine for yourself whether the timing of the Vaxinia updates are suspicious.
Here are the original terms of agreement for Vaxinia shareholders to receive shares as per clinical milestones for CF33. There is clear evidence that CHECKvacc could have been used as a vehicle to obtain shares. IMU shareholders received no official communications regarding its effects in TNBC despite woeful efficacy and discontinuation of the clinical program at only 9 patients treated.
119,354,838 shares will be issued upon the allowance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for CF33, no later than June 30, 2021.In preparation for an EGM, here is a letter from Leslie Chong recommending shareholders vote in favor of awarding Vaxinia shareholders with 120M shares despite the IND for CHECKvacc being late. Shareholders voted in favor of this and since then the company has provided no meaningful communications on CHECKvacc clinical program to determine efficacy. Clearly, without CHECKvacc, the Vaxinia shareholders would not have been able to receive shares as the Vaxinia IND was not received before June 30 2021.
134,258,064 shares will be issued upon the dosing of the first patient in a Phase 1 Clinical Trial for CF33, no later than March 31, 2022.Clearly, without the CHECKvacc clinical program, the Vaxinia shareholders would not have received shares since first patient was dosed after March 31 2022.
149193548 shares will be issued upon Imugene achieving Phase 1 safety endpoints (excluding efficacy and dose) for CF33, no later than June 30, 2024.IMU shareholders received clinical trial updates in November 2023 and January of 2024. On the first of Feb, 2024, IMU management awarded Vaxinia shareholders with 149M shares for demonstrating primary safety endpoints and state specifically that they have not disclosed information from the Vaxinia trial to confirm whether the conditions have been satisfactorily met. Why did IMU management not wait until closer to June 30 2024 so that they could accurately and honestly inform shareholders so that they themsevles may determine whether the criteria for the issuance of shares had been met?
IMU management provided 2 open label clinical trial updates no more than 3 months before they awarded Vaxinia shareholders with 149M shares while admitting that they have not disclosed the required information to confirm whether the criteria had been met. IMU management have failed to further update the market for more than 12 months on the Vaxinia MAST trial despite numerous more patients being dosed and data collected. Also, the CHECKvacc trial was halted and discontinued without shareholders being made aware.
Professor Yuman Fong sold every single one of his shares on market to retail shareholders, pocketing an estimated $10M AUD. As of the last update, he has 22.4M shares which were awarded 1st Feb 2024.
Paul Hopper sold $35M AUD worth of shares into retail shareholders, and has loaned out a huge portion to fund personal endeavours.
This paints a pretty disgusting picture, and is a huge reason why I continue to post. When will IMU shareholders be shown the simplest of respect for the hard earned cash they invested?
(20min delay)